BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 37619953)

  • 21. Lactococcus lactis carrying the pValac DNA expression vector coding for IL-10 reduces inflammation in a murine model of experimental colitis.
    Zurita-Turk M; Del Carmen S; Santos AC; Pereira VB; Cara DC; Leclercq SY; de LeBlanc Ad; Azevedo V; Chatel JM; LeBlanc JG; Miyoshi A
    BMC Biotechnol; 2014 Aug; 14():73. PubMed ID: 25106058
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral Tolerance Induced by Heat Shock Protein 65-Producing
    Guerra PV; Andrade CM; Nunes IV; Gama BC; Tibúrcio R; Santos WLC; Azevedo VA; Tavares NM; Rebouças JS; Maiolii TU; Faria AMC; Brodskyn CI
    Front Immunol; 2021; 12():647987. PubMed ID: 34248935
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Secretion of an immunoreactive single-chain variable fragment antibody against mouse interleukin 6 by Lactococcus lactis.
    Shigemori S; Ihara M; Sato T; Yamamoto Y; Nigar S; Ogita T; Shimosato T
    Appl Microbiol Biotechnol; 2017 Jan; 101(1):341-349. PubMed ID: 27722916
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mucosal delivery of Lactococcus lactis carrying an anti-TNF scFv expression vector ameliorates experimental colitis in mice.
    Chiabai MJ; Almeida JF; de Azevedo MGD; Fernandes SS; Pereira VB; de Castro RJA; Jerônimo MS; Sousa IG; de Souza Vianna LM; Miyoshi A; Bocca AL; Maranhão AQ; Brigido MM
    BMC Biotechnol; 2019 Jun; 19(1):38. PubMed ID: 31238939
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trimming of two major type 1 diabetes driving antigens, GAD65 and IA-2, allows for successful expression in Lactococcus lactis.
    Robert S; Van Huynegem K; Gysemans C; Mathieu C; Rottiers P; Steidler L
    Benef Microbes; 2015; 6(4):591-601. PubMed ID: 25576592
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hsp65-Producing
    Gusmao-Silva G; Aguiar SLF; Miranda MCG; Guimarães MA; Alves JL; Vieira AT; Cara DC; Miyoshi A; Azevedo VA; Oliveira RP; Faria AMC
    Front Immunol; 2020; 11():562905. PubMed ID: 33072101
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular mechanisms of cytokine and chemokine release from eosinophils activated by IL-17A, IL-17F, and IL-23: implication for Th17 lymphocytes-mediated allergic inflammation.
    Cheung PF; Wong CK; Lam CW
    J Immunol; 2008 Apr; 180(8):5625-35. PubMed ID: 18390747
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetically engineered Lactococcus lactis protect against house dust mite allergy in a BALB/c mouse model.
    Ai C; Zhang Q; Ren C; Wang G; Liu X; Tian F; Zhao J; Zhang H; Chen YQ; Chen W
    PLoS One; 2014; 9(10):e109461. PubMed ID: 25290938
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Secretion of biologically active human interleukin 22 (IL-22) by Lactococcus lactis.
    Loera-Arias MJ; Villatoro-Hernández J; Parga-Castillo MA; Salcido-Montenegro A; Barboza-Quintana O; Muñoz-Maldonado GE; Montes-de-Oca-Luna R; Saucedo-Cárdenas O
    Biotechnol Lett; 2014 Dec; 36(12):2489-94. PubMed ID: 25214209
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune Responses to Orally Administered Recombinant
    Zhang F; Zhang Z; Li X; Li J; Lv J; Ma Z; Pan L
    Viruses; 2021 Oct; 13(10):. PubMed ID: 34696469
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The protective effect of recombinant Lactococcus lactis oral vaccine on a Clostridium difficile-infected animal model.
    Yang XQ; Zhao YG; Chen XQ; Jiang B; Sun DY
    BMC Gastroenterol; 2013 Jul; 13():117. PubMed ID: 23865596
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10.
    Steidler L; Hans W; Schotte L; Neirynck S; Obermeier F; Falk W; Fiers W; Remaut E
    Science; 2000 Aug; 289(5483):1352-5. PubMed ID: 10958782
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of IL-17A, IL-17F, and the IL-17 receptor in regulating growth-related oncogene-alpha and granulocyte colony-stimulating factor in bronchial epithelium: implications for airway inflammation in cystic fibrosis.
    McAllister F; Henry A; Kreindler JL; Dubin PJ; Ulrich L; Steele C; Finder JD; Pilewski JM; Carreno BM; Goldman SJ; Pirhonen J; Kolls JK
    J Immunol; 2005 Jul; 175(1):404-12. PubMed ID: 15972674
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Engineering recombinant Lactococcus lactis as a delivery vehicle for BPC-157 peptide with antioxidant activities.
    Škrlec K; Ručman R; Jarc E; Sikirić P; Švajger U; Petan T; Perišić Nanut M; Štrukelj B; Berlec A
    Appl Microbiol Biotechnol; 2018 Dec; 102(23):10103-10117. PubMed ID: 30191288
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the local immune response against Giardia lamblia cyst wall protein 2 induced by recombinant Lactococcus lactis and Streptococcus gordonii.
    Lee P; Abdul-Wahid A; Faubert GM
    Microbes Infect; 2009 Jan; 11(1):20-8. PubMed ID: 18992359
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetically modified Lactococcus lactis producing a green fluorescent protein-bovine lactoferrin fusion protein suppresses proinflammatory cytokine expression in lipopolysaccharide-stimulated RAW 264.7 cells.
    Shigemori S; Namai F; Yamamoto Y; Nigar S; Sato T; Ogita T; Shimosato T
    J Dairy Sci; 2017 Sep; 100(9):7007-7015. PubMed ID: 28690060
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induction of ovalbumin-specific tolerance by oral administration of Lactococcus lactis secreting ovalbumin.
    Huibregtse IL; Snoeck V; de Creus A; Braat H; De Jong EC; Van Deventer SJ; Rottiers P
    Gastroenterology; 2007 Aug; 133(2):517-28. PubMed ID: 17681173
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lactococcus lactis as a cell factory for delivery of therapeutic proteins.
    Bahey-El-Din M; Gahan CG; Griffin BT
    Curr Gene Ther; 2010 Feb; 10(1):34-45. PubMed ID: 20156189
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevention and treatment of colitis with Lactococcus lactis secreting the immunomodulatory Yersinia LcrV protein.
    Foligne B; Dessein R; Marceau M; Poiret S; Chamaillard M; Pot B; Simonet M; Daniel C
    Gastroenterology; 2007 Sep; 133(3):862-74. PubMed ID: 17678918
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Engineered lactic acid bacterium Lactococcus lactis capable of binding antibodies and tumor necrosis factor alpha.
    Ravnikar M; Strukelj B; Obermajer N; Lunder M; Berlec A
    Appl Environ Microbiol; 2010 Oct; 76(20):6928-32. PubMed ID: 20802083
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.